Improvement of the Chemical Reactivity of Michael Acceptor of Ethacrynic Acid Correlates with Antiproliferative Activities

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Jan 21

PMID 36677966

Authors

Abdelmoula El Abbouchi

Nabil El Brahmi

Marie-Aude Hiebel

Hamza Ghammaz

Elmostafa El Fahime

Jerome Bignon

Gerald Guillaumet

Franck Suzenet

Said El Kazzouli

Affiliations

Soon will be listed here.

Abstract

The present study aims to report the design, synthesis, and biological activity of new ethacrynic acid () analogs () obtained by the double modulation of the carboxylic acid moiety and the aromatic ring with the aim to increase the chemical reactivity of Michael acceptor of . All obtained compounds were characterized by H and C NMR, IR, and high-resolution mass spectrometry. The antiproliferative activity was evaluated in vitro using MMT test, in a first step, against HL60 cell line and in a second step, on a panel of human cancer cell lines such as HCT116, A549, MCF7, PC3, U87-MG, and SKOV3, and normal cell line MRC5 in comparison with positive control doxorubicin. Among all the tested compounds, the product containing a propargyl and a hydroxyl groups, allowing an intramolecular hydrogen bond with the keto group of , exhibited a pronounced and selective activity in a nanomolar range against HL60, A549, PC3, and MCF7 with IC values of 15, 41.2, 68.7, and 61.5 nM, respectively. Compound also showed a good selectivity index (SI) against HL60 and moderate SI against the other three human cancer cells (A549, PC3, and MCF7). The study of the structure-activity relationship showed that both modifications of the carboxylic group and the introduction of an intramolecular hydrogen bond are highly required to improve the antiproliferative activities. The molecular modeling studies of compound revealed that it favorably binds to the glutathione S-transferase active site, which may explain its interesting anticancer activity. These new compounds have potential to be developed as novel therapeutic agents against various cancer types.

Citing Articles

Michael Acceptor Pyrrolidone Derivatives and Their Activity against Diffuse Large B-cell Lymphoma.

Zhang B, Wang F, Yin J, Yu X, Hu Z, Gu L Curr Med Sci. 2024; 44(5):890-901.

PMID: 39285051 DOI: 10.1007/s11596-024-2922-y.

Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.

Chihab A, El Brahmi N, Hamdoun G, El Abbouchi A, Ghammaz H, Touil N RSC Adv. 2024; 14(37):26829-26836.

PMID: 39184001 PMC: 11342919. DOI: 10.1039/d4ra04938a.

In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells.

Wei X, Wang W, Yin Q, Li H, Ahmed A, Ullah R Int J Mol Sci. 2024; 25(14).

PMID: 39063039 PMC: 11277044. DOI: 10.3390/ijms25147798.

Design, Synthesis, Computational Studies, and Anti-Proliferative Evaluation of Novel Ethacrynic Acid Derivatives Containing Nitrogen Heterocycle, Urea, and Thiourea Moieties as Anticancer Agents.

El Abbouchi A, Mkhayar K, Elkhattabi S, El Brahmi N, Hiebel M, Bignon J Molecules. 2024; 29(7).

PMID: 38611717 PMC: 11013014. DOI: 10.3390/molecules29071437.

Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent.

Yu L, Lee H, Rho S, Park M, Lee C Int J Mol Sci. 2023; 24(7).

PMID: 37047688 PMC: 10094867. DOI: 10.3390/ijms24076712.

References

Bose P, Ozer H . Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs. 2009; 18(11):1735-51. DOI: 10.1517/13543780903305428. View

Tew K . Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54(16):4313-20. View

Ploemen J, van Schanke A, van Ommen B, van Bladeren P . Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P1-1. Cancer Res. 1994; 54(4):915-9. View

Swyka R, Shuler W, Spinello B, Zhang W, Lan C, Krische M . Conversion of Aldehydes to Branched or Linear Ketones via Regiodivergent Rhodium-Catalyzed Vinyl Bromide Reductive Coupling-Redox Isomerization Mediated by Formate. J Am Chem Soc. 2019; 141(17):6864-6868. PMC: 6602061. DOI: 10.1021/jacs.9b03113. View

Rashid H, Xu Y, Muhammad Y, Wang L, Jiang J . Research advances on anticancer activities of matrine and its derivatives: An updated overview. Eur J Med Chem. 2018; 161:205-238. DOI: 10.1016/j.ejmech.2018.10.037. View

Hawash M, Jaradat N, Eid A, Abubaker A, Mufleh O, Al-Hroub Q . Synthesis of novel isoxazole-carboxamide derivatives as promising agents for melanoma and targeted nano-emulgel conjugate for improved cellular permeability. BMC Chem. 2022; 16(1):47. PMC: 9229817. DOI: 10.1186/s13065-022-00839-5. View

Herman S, Mustafa R, Gyamfi J, Pittaluga S, Chang S, Chang B . Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014; 123(21):3286-95. PMC: 4046423. DOI: 10.1182/blood-2014-02-548610. View

Oakley A, Rossjohn J, Lo Bello M, Caccuri A, Federici G, Parker M . The three-dimensional structure of the human Pi class glutathione transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate. Biochemistry. 1997; 36(3):576-85. DOI: 10.1021/bi962316i. View

Mignani S, El Brahmi N, El Kazzouli S, Eloy L, Courilleau D, Caron J . A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action. Eur J Med Chem. 2016; 122:656-673. DOI: 10.1016/j.ejmech.2016.05.063. View

10.

Saleh L, Wang W, Herman S, Saba N, Anastas V, Barber E . Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia. 2016; 31(2):340-349. PMC: 9119706. DOI: 10.1038/leu.2016.181. View

11.

Hurvitz S, Shatsky R, Harbeck N . Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs. 2014; 23(7):1039-47. DOI: 10.1517/13543784.2014.924505. View

12.

El Abbouchi A, El Brahmi N, Hiebel M, Bignon J, Guillaumet G, Suzenet F . Synthesis and evaluation of a novel class of ethacrynic acid derivatives containing triazoles as potent anticancer agents. Bioorg Chem. 2021; 115:105293. DOI: 10.1016/j.bioorg.2021.105293. View

13.

DArcangelo M, Hirsch F . Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics. 2014; 8:183-92. PMC: 4003149. DOI: 10.2147/BTT.S40567. View

14.

Eberhardt J, Santos-Martins D, Tillack A, Forli S . AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021; 61(8):3891-3898. PMC: 10683950. DOI: 10.1021/acs.jcim.1c00203. View

15.

Zhang S, Neumann H, Beller M . Synthesis of α,β-unsaturated carbonyl compounds by carbonylation reactions. Chem Soc Rev. 2020; 49(10):3187-3210. DOI: 10.1039/c9cs00615j. View

16.

Ang W, Khalaila I, Allardyce C, Juillerat-Jeanneret L, Dyson P . Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc. 2005; 127(5):1382-3. DOI: 10.1021/ja0432618. View

17.

Wang T, Arifoglu P, Ronai Z, Tew K . Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem. 2001; 276(24):20999-1003. DOI: 10.1074/jbc.M101355200. View

18.

El Brahmi N, Mignani S, Caron J, El Kazzouli S, Bousmina M, Caminade A . Investigations on dendrimer space reveal solid and liquid tumor growth-inhibition by original phosphorus-based dendrimers and the corresponding monomers and dendrons with ethacrynic acid motifs. Nanoscale. 2014; 7(9):3915-22. DOI: 10.1039/c4nr05983b. View

19.

Sakaeda T, Okamura N, Nagata S, Yagami T, Horinouchi M, Okumura K . Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Biol Pharm Bull. 2001; 24(8):935-40. DOI: 10.1248/bpb.24.935. View

20.

Kaeppler U, Stiefl N, Schiller M, Vicik R, Breuning A, Schmitz W . A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. J Med Chem. 2005; 48(22):6832-42. DOI: 10.1021/jm0501782. View